Harmony Biosciences Holdings (HRMY) Total Debt (2019 - 2026)

Harmony Biosciences Holdings has disclosed Total Debt across 8 years of filings, most recently posting $158.8 million for Q1 2026.

• Total Debt for Q1 2026 came in at $158.8 million, down 9.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $158.8 million (down 9.6% YoY), and the FY2025 annual result was $163.7 million, down 8.7% from the prior year.
• Total Debt came in at $158.8 million for Q1 2026 at Harmony Biosciences Holdings, down from $163.7 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $197.1 million in Q3 2023 to a low of $158.8 million in Q1 2026.
• The 5-year median for Total Debt is $190.0 million (2024), against an average of $183.4 million.
• Across the five-year window, Total Debt grew 2.82% in 2023 and slipped 9.6% in 2026, its largest moves.
• Harmony Biosciences Holdings' Total Debt stood at $191.6 million in 2022, then grew by 1.0% to $193.6 million in 2023, then decreased by 7.39% to $179.3 million in 2024, then retreated by 8.7% to $163.7 million in 2025, then decreased by 2.96% to $158.8 million in 2026.
• The last three Total Debt figures came in at $158.8 million (Q1 2026), $163.7 million (Q4 2025), and $168.5 million (Q3 2025), per Business Quant data.